GBT Announces New Employment Inducement Grants
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff pulls Wall Street to two-week lows as oil and yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- Francisco Partners to acquire Weave Communications for $650M
Global Blood Therapeutics (GBT) PT Lowered to $74 at Oppenheimer
May 8, 2018 7:51 AM EDTOppenheimer lowered its price target on Global Blood Therapeutics (NASDAQ: GBT) to $74.00 (from $79.00) while maintaining a Outperform rating.
Analyst Mark Breidenbach commented, "Monday, Global Blood announced 1Q18 financial results and we discussed upcoming milestones with management. Results from the first 150... More
